Probiotic agents to protect the urogenital tract against infection

Gregor Reid

ABSTRACT  The urogenital microflora of a healthy woman comprises ~50 species of organisms, which differ in composition according to reproductive stages and exposure to several factors, including antibiotics and spermicides. Infections are very common with >300 million cases of urinary tract infections, bacterial vaginosis, and yeast vaginitis worldwide per annum. At the time of infection in the bladder and vagina, the urogenital flora is often dominated by the infecting pathogens, in contrast with healthy phases when indigenous organisms dominate. Premenopausal women have a flora of mostly lactobacilli, and certain properties of these strains, including adhesive ability and production of acids, bacteriocins, hydrogen peroxide, and biosurfactants, appear important in conferring protection to the host. Efforts to artificially restore an unbalanced flora with the use of probiotics have met with mixed results but research aimed at selecting scientifically based strains could well provide a reliable alternative treatment and preventive regimen to antibiotics in the future. Am J Clin Nutr 2001;73(suppl):437S–43S.

KEY WORDS  Urogenital flora, infection, urinary tract, bacterial vaginosis, lactobacilli, probiotics

UROGENITAL INFECTIONS

Urogenital infections, defined here to include those that affect the bladder, kidneys, vagina, urethra, perirethra, and cervix, constitute a worldwide problem that affects >300 million women/y. In Western countries such as Canada and the United States, these infections are a common reason for a woman’s visit to a family practitioner or urologist. For those infections in the urinary tract, it has been estimated that each episode leads to 6 d of signs and symptoms (1). The main clinical outcome is morbidity and discomfort amongst a large percentage of the female population, in addition to enormous costs to the health care system for treatment.

Many patients will experience a recurrence of symptoms, particularly within the first year of the original infection. Of more concern are infections that are complicated by kidney involvement because hospitalization is usually required and kidney damage or even death can occur. Serious complications can arise during pregnancy, sometimes leading to premature birth (2).

Historical data indicate that the vast majority (~70%) of urinary tract infection (UTI) in a suburban, nonhospitalized community is caused by Escherichia coli, followed by other enterobacteriaceae and Staphylococcus saprophyticus. However, a recent 7 y study indicated a different result, whereby E. coli infections were less common and Enterococcus faecalis was the second most prevalent uropathogen (3). The latter result was also found in hospitalized patients (4).

Most uncomplicated UTI cases are resolved between 1 and 7 d of antibiotic therapy. However, drug resistance to commonly used antibiotics (eg, trimethoprim/sulfamethoxazole) is increasing among uropathogens (3) and patients are experimenting more and more with alternative natural remedies such as cranberry juice, which appears to contain antiadhesive compounds that are active against uropathogens and can help prevent UTI (5–8).

Currently, preventive therapies for UTI rely almost exclusively on the use of antibiotics. In real terms, no true prophylaxis exists: current therapy involves long-term, low-dose antibiotic treatment, which involves the active killing of bacteria that enter the bladder.

Bacterial vaginosis (BV), formerly referred to as nonspecific vaginitis (9), is a major cause of urogenital disease in females. It has been defined as a mild infection of the lower female genital tract, characterized by the presence of 3 of 4 criteria to define urogenital disease: 1) release of an amine (putrescine, cadaverine, and trimethylamine) or fishy odor after the addition of 10% potassium hydroxide, 2) a vaginal pH >4.5, 3) clue cells in the vaginal fluid, and 4) a milky homogeneous vaginal discharge (10, 11). The clue-cell scoring of the cell population is termed as either normal (0–3; dominated by lactobacilli rods), intermediate (4–6; colonization by small gram-negative or gram-variable rods, eg, Bacteroides or Gardnerella, and curved gram-variable rods, eg, Mobiluncus), or BV (7–10; dominated by pathogens) (12).

The diagnosis of BV has its flaws (11, 13) and future improvements with the use of DNA probes, fast and accurate detection of amines, and short-chain volatile acids and enzymes should make diagnosis easier and more reliable for BV and other urogenital pathogens, eg, Chlamydia trachomatis, Neisseria gonorrhoeae, herpes simplex virus, HIV, papillomavirus, Treponema pallidum, and Trichomonas vaginalis (14–18).

BV can lead to complications in pregnancies, causing premature rupture of the membranes, premature birth, or the death of the fetus or newborn (19–24). Premature rupture of the...
membranes can also be associated with BV, urinary tract infections, group B streptococcal infections, and the presence of organisms such as ureaplasma and mycoplasma in the urogenital tract (25–32).

DYNAMICS OF THE UROGENITAL MICROFLORA

The origin of the uropathogens in uncomplicated UTI and BV is the fecal flora. For >20 y, the key factor in pathogenesis has been regarded as the ability of the pathogens to attach to epithelial cells, thereby allowing them a niche in which to establish, multiply, spread, and avoid host defenses (33, 34). Numerous studies have investigated and documented the adhesins and receptor sites involved in the attachment process. Factors such as hemolysins, aerobactin, capsular antigens, and others play a role in E. coli pathogenesis in UTI (35–42). Furthermore, there are host susceptibility factors, including genetic determinants, age-related changes, and mucosal differences that influence the infection process (43).

Although the adhesion phenomenon is unquestionably important, there appears to be another key element of pathogenesis that is less well understood, namely the ability of the pathogens to survive exposure to the microflora that exists on the external urogenitalia. It has been reported that >50 species colonize the healthy vagina (44). Studies have shown that urogenital cells are covered by dense bacterial biofilms (45, 46) whose composition changes constantly but in which lactobacilli predominate, at least until menopause. Uropathogenic organisms emerge from the intestine (47) and come into contact with these biofilms on vaginal and urethral cells, yet little is known about what happens thereafter. It is presumed that uropathogens can either bypass the microflora or successfully enter the biofilms, survive, and continue their ascension into the bladder.

Biofilms have been described in the human host for >20 y (48, 49) but their role in health has not been studied as well as their association with disease. Current understanding indicates that the structure and dynamics of biofilms vary with the organisms, the surface to which they attach, the nutritional environment, and shear forces present in any given case. The organisms appear to benefit from biofilm formation by gaining access to nutrients, escaping host immune cells and antimicrobial attack, and having an ability to better control their multiplication. A recurrent theme is that various factors, including nutrients, antimicrobials, and arriving bacteria, change the properties and the composition of the biofilms. In women, other factors such as hormonal concentrations, particularly estrogen, as well as changes induced by oral contraception, glycogen content, vaginal pH, steroid therapy, immunosuppression, and diseases (eg, diabetes mellitus) all influence the composition of the bacterial biofilms (50). The menstrual cycle appears to affect the adherence of lactobacilli to epithelial cells in healthy women in that days corresponding to high circulating concentrations of estrogens result in a higher adherence in vitro (51) and restored colonization postmenopause (52).

Studies have shown that antibiotic or spermicide exposure can cause disruption of the urogenital microflora and increase a woman’s risk of infection (53, 54). Indeed, in vitro studies showed that most lactobacilli are eradicated by exposure to a low dose of nonoxynol-9, whereas uropathogens grow and prosper in high concentrations of this compound (55). Thus, protection of the host by her vaginal Lactobacillus flora is likely reduced upon exposure to spermicides. The fact that antimicrobials do not always completely wipe out the urogenital flora is due not only to resistance of individual strains, but also likely to the existence of biofilms, which themselves confer resistance to attack (56).

Scanning confocal laser microscopy has shown that biofilms are mushroom shaped and form water channels through which the organisms are nourished (57–59). With the use of such techniques, it should be possible to follow the entry of a uropathogen into the urogenital biofilm system, from whence it infects the host (Figure 1).

LACTOBACILLI AS GOOD PROBIOTICS FOR PREVENTION OF UROGENITAL INFECTIONS

The dominant presence of lactobacilli in the urogenital microflora of healthy women and the obliteration of lactobacilli in patients who develop UTI (60–62), BV, and many other genitai infections (30, 63) [except candidiasis (64)] has led to a focus on these bacteria. Lactobacilli are gram-positive rods, primarily facultative or strict anaerobes that generally have a fastidious
growth requirement. They prefer an acidic environment and help create one by producing lactic and other acids. In general, lactobacilli have not been associated with disease and for >100 y have been regarded as nonpathogenic members of the intestinal and urogenital floras (65).

Lactobacilli have long been of interest to the dairy and agriculture industries (66, 67), although over the past century, studies in relation to human health were sporadic and often inconclusive. Some examples can be found in which lactic acid bacteria have been used to treat or prevent infections of the intestinal and genital tracts with different degrees of success (68–71). However, there has been failure in identifying the properties of lactobacilli required to prevent and treat disease; in determining the optimal dosage, duration, and mode of lactobacilli delivery; and including a placebo in the study. Studies have failed to recover and document lactobacilli properly and show their mechanisms of action.

A further problem with probiotic therapeutics is their reliability. In one study, this was highlighted by the fact that the contents of some health food products were inconsistent and different from those stated on the labels (72). More recently, we discovered that some health food products in Canada appear to contain ≥ 1 common Lactobacillus strain, apparently identical to ATCC strain 21052, and that US and Canadian products contain Lactobacillus plantarum, although its presence is not stated on the food label (73).

In more recent years, the use of probiotics per se and lactobacilli specifically has received greater attention as an alternative, inexpensive, and natural remedy to restore and maintain health (74–79). Two strains, Lactobacillus GG (ATCC 53103) and Lactobacillus rhamnosus GR-1 appear to be effective at colonizing and protecting the intestine (80–86) and urogenital tract (87–91), respectively, against microbial infection. Studies in relation to human health were sporadic and often inconclusive. Some examples can be found in which lactic acid bacteria have been used to treat or prevent infections of the intestinal and genital tracts with different degrees of success (68–71). However, there has been failure in identifying the properties of lactobacilli required to prevent and treat disease; in determining the optimal dosage, duration, and mode of lactobacilli delivery; and including a placebo in the study. Studies have failed to recover and document lactobacilli properly and show their mechanisms of action.

There is one obvious question: what properties do these strains possess that make them effective probiotic agents? The answer is not fully known, but some common denominators appear to exist, namely the ability to adhere to and colonize tissues and the capacity to inhibit the pathogenesis of disease-causing organisms (Figure 2). Another question can be raised: do we expect an exogenous probiotic strain to colonize the gastrointestinal and urogenital tracts of a given person for a long time and even become part of the normal flora, replacing or coexisting with the endogenous lactobacilli organisms? Or is the aim to substitute the endogenous bacteria only while the normal flora is repressed (eg, as a result of antibiotic therapy) (92)? Again, no clear answers are available.

To more fully ascertain which properties are required by lactobacilli to protect the host, we recommend a series of extensive microbiological, physico-chemical, and molecular biology methodologies (89, 93–97). It appears that a given strain of Lactobacillus can express several, but not necessarily all, of the known key factors and be able to compete in the urogenital microenvironment. For example, lactobacilli can use many mechanisms to adhere to surfaces, such as electrostatic, hydrophobic, hydrophilic, capsular, and fimbrial mechanisms (95, 98–102): in the urogenital tract, hydrophilic L. rhamnosus GR-1 and hydrophobic Lactobacillus fermentum B-54 both colonize (91). Some strains can bind better to intestinal cells and inhibit pathogen adhesion (103, 104), but they may not be able to effectively inhibit growth of uropathogens (94).

Before commencing more human studies, L. rhamnosus GR-1 was found to be the best of a group of 34 Lactobacillus strains isolated from dairy, poultry, health food, and human sources, with respect to adhesion to squamous and transitional uroepithelial cells, competitive exclusion of pathogens, and production of inhibitors of uropathogen growth (94). In 1995 another characteristic of lactobacilli was discovered that appeared to be important in conferring probiotic action against uropathogens. Fifteen strains were found to produce biosurfactant (105). The substance or substances adsorbed to surfaces and inhibited the initial adhesion of E. faecalis by 70%. The crude substance was analyzed and found to contain proteins and carbohydrates. Amino acid analysis of hydrolyzed material from strain Lactobacillus acidophilus RC-14 showed a high alanine content compared with less active strains. The activity is not due to lipoteichoic acid or glycosyldiglycerides or to factors such as acid or bacteriocins, which inhibit bacterial growth. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis showed a variety of proteins with molecular masses of from 14.4 to 140 kDa (106, 107). The biosurfactant activity is resistant to trypsin and pepsin, and sensitive to α-amylase and lysozyme, and resistant to 75°C degree heating. The antiahesive molecules produced by certain lactobacilli hold promise for application to many human sites where pathogens attach, colonize, and confer disease. More recently, the activity was shown to affect a broad range of pathogens (Table 1) (108) and an active component was found to be a collagen binding protein (109).
argue that the strains that appear in stool and in vaginal mucosa throughout life are those that colonized the urogenital tract shortly after birth, and that subsequent events, eg, nutritional and hormonal changes, led to the emergence or suppression of certain strains. A lengthy and large epidemiologic study might be needed to better understand the succession of the normal flora during different phases of life.

There is an indication that probiotic strains can undergo genetic changes during colonization: a tetracycline-sensitive Bifidobacterium strain administered to antibiotic-decontaminated mice maintained in isolators was found to produce 2 undistinguished intestinal populations according to restriction endonuclease patterns of total DNA, but one variant was highly resistant to tetracycline (V Smeianov et al, unpublished observations, 1998). Both variants coexisted in the mouse intestine and there was a strong advantage of the newly appeared variant. This possibility of genetic adaptation or in vivo selection of probiotic bacteria is an area of interest for our group.

We assume that artificial colonization is possible and that in vitro analyses will allow us to construct methods for selecting and delivering these strains. However, an adjunct to such studies must be an examination of the strains already colonizing healthy humans and a clarification of how these organisms are altered by food intake. On the basis of our knowledge, strains with different origins and probiotic properties seem to exist in the vagina of healthy women (73, 116). The challenge will be to identify which strains are the most beneficial for health and why.

Further proof of urogenital colonization and protection from infection was obtained from a clinical trial in which 55 premenopausal women were given weekly either one suppository of L. rhamnosus GR-1 and B-54 (0.5 g) or one suppository of a lactobacillus growth factor for 1 y. The patients were followed up after 2 wk and then monthly (91). Six patients were excluded in the first month for noncompliance, moving, or becoming pregnant, and 11 patients did not complete the study in full; however, their data were included to examine infection rates. Again, there were no side effects in the study. The UTI infection rate decreased from 6.0 per previous year to 1.6 (73% decrease) for those given lactobacilli and to 1.3 (79% decrease) for those given Lactobacillus growth factor. Time to first infection was the same in both groups, namely 21–22 wk. Vaginal pH was the same for both groups, namely 4.6–5.0. The viable lactobacillus counts recovered from vaginal swabs increased with therapy, especially for months 7–12 for lactobacilli-treated patients, during which time lower UTI rates were seen.

CONCLUSIONS

There is now growing evidence that certain species and strains present in the healthy urogenital tract protect the host against

---

**TABLE 1**

Pathogens affected by biosurfactant activity

<table>
<thead>
<tr>
<th>Strain</th>
<th>Adhesion (4 h) $\times 10^6$ cm$^{-2}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Escherichia coli 67</td>
<td></td>
</tr>
<tr>
<td>No biosurfactant</td>
<td>2.4</td>
</tr>
<tr>
<td>With biosurfactant</td>
<td>0.5</td>
</tr>
<tr>
<td>E. coli Hu734</td>
<td>1.1</td>
</tr>
<tr>
<td>No biosurfactant</td>
<td></td>
</tr>
<tr>
<td>With biosurfactant</td>
<td>0.2</td>
</tr>
<tr>
<td>Enterococcus faecalis 1131</td>
<td>1.04</td>
</tr>
<tr>
<td>No biosurfactant</td>
<td></td>
</tr>
<tr>
<td>With biosurfactant</td>
<td>0.04</td>
</tr>
<tr>
<td>E. faecalis 1396</td>
<td>0.3</td>
</tr>
<tr>
<td>With biosurfactant</td>
<td>0.02</td>
</tr>
<tr>
<td>Klebsiella pneumoniae 3a</td>
<td>0.9</td>
</tr>
<tr>
<td>No biosurfactant</td>
<td></td>
</tr>
<tr>
<td>With biosurfactant</td>
<td>0.7</td>
</tr>
<tr>
<td>Proteus mirabilis 28cii</td>
<td>1.0</td>
</tr>
<tr>
<td>No biosurfactant</td>
<td></td>
</tr>
<tr>
<td>With biosurfactant</td>
<td>0.5</td>
</tr>
<tr>
<td>Providencia stuartii UHL103</td>
<td>8.9</td>
</tr>
<tr>
<td>No biosurfactant</td>
<td></td>
</tr>
<tr>
<td>With biosurfactant</td>
<td>4.0</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa AK1</td>
<td>11.0</td>
</tr>
<tr>
<td>No biosurfactant</td>
<td></td>
</tr>
<tr>
<td>With biosurfactant</td>
<td>9.5</td>
</tr>
<tr>
<td>Staphylococcus epidermidis 3059</td>
<td>1.8</td>
</tr>
<tr>
<td>No biosurfactant</td>
<td></td>
</tr>
<tr>
<td>With biosurfactant</td>
<td>0.2</td>
</tr>
</tbody>
</table>

*See reference 104.
infection by pathogenic microorganisms. Many properties required to confer this protection have been identified, but evidence of their expression in vivo is scant and the relative significance of each is unknown. The concept of treating and preventing urogenital infection by instilling probiotic organisms has great appeal to patients and caregivers. The ability to administer L. rhamnosus GR-1 and L. fermentum RC-14, which colonize the intestine and vagina, by mouth to help restore and maintain urogenital health (118) provides a major step in the right direction for patients as it potentially allows for the self-administration of therapy. However, for this approach to be successful, proper selection of strains, proof of concept, and efficacy must accompany products used in patients.

REFERENCES


UROGENITAL TRACT PROTECTION BY PROBIOTICS 443S

89. Reid G, Millsap K, Bruce AW. Implantation of Lactobacillus casei var rhamnosus into vagina. Lancet 1994;344:1229 (letter).


98. Velraeds MM, van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis to solid substrate by an adsorbed biosurfactant layer from Lactobacillus acidophilus. Urology 1997;49:790–4.